1. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study 
Sumathi Sivapalasingam, MD, Mohamed Kamal, PhD, Rabih Slim, PhD, Romana Hosain, MD, Weiping Shao, PhD, Randall Stoltz, MD, Joseph Yen, PhD, Laura G Pologe, PhD, Yuan Cao, PhD, Michael Partridge, PhD, Giane Sumner, PhD, Leah Lipsich, PhD 
The Lancet Infectious Diseases 
Volume 18, Issue 8, Pages (August 2018)
DOI: /S (18)
Copyright © 2018 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
Cohort 1: REGN mg/kg IV or placebo IV infused over 2 h. Cohort 2: REGN mg/kg IV or placebo IV infused over 2 h. Cohort 3: REGN mg/kg IV or placebo IV infused over 4 h. Cohort 4: REGN mg/kg IV or placebo IV infused over 4 h. IV=intravenous.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions

3. Figure 2
Mean log-scaled concentrations of total REGN3470, total REGN3471, and total REGN3479 in serum from healthy adults, by nominal time and treatment group
Error bars show the SD of each mean. LLOQ=lower limit of quantification.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions